The numbers coming out of Rocket Lab’s operations read like a triumph. The stock chart reads like a disaster. That dissonance has rarely been starker than this week, as the space company’s shares closed at €56.40 on Friday — a single-session drop of 8.29% that extended the monthly decline to roughly 24%. From the May peak of €133.80, the equity has now surrendered nearly 58% of its value.
The selloff has been so aggressive that the relative strength index has plunged to 30.8, deep into oversold territory. The 200-day moving average, a proxy for the medium-term trend, sits at roughly €67.37 — more than 16% above the current price. That gap suggests the structural trend remains healthier than the recent panic implies, even if the short-term pain has been brutal.
Neutron Anxiety Overwhelms a Record Quarter
What’s driving the exodus? The same factor that has dominated Rocket Lab’s narrative for months: the Neutron rocket. The company is targeting a first flight in the fourth quarter of 2026, but whispers about certification delays and missed test milestones have amplified investor jitters. CEO Peter Beck has repeatedly framed the shift from component production to full assembly on the test stand as the critical progress indicator. For now, the market is pricing in the worst-case timeline.
Yet the operational picture tells a different story. In July, Rocket Lab completed the VICTUS-HAZE mission for the US Space Force, launching an Electron rocket just 16 hours and 42 minutes after receiving the go order — a new industry benchmark for rapid-response space operations. That same month, the company secured a $266 million contract from the US Air Force, adding to a backlog that stood at roughly $1.42 billion at the start of the year. By the time of the first-quarter earnings call, that backlog had swelled to $2.2 billion, supported by more than $2 billion in available liquidity.
The contrast is jarring: a business that is winning contracts, setting operational records, and carrying enough cash to fund additional Neutron qualification work is being treated by the market as if it were in crisis.
The Analyst Divide
Wall Street’s official view remains overwhelmingly bullish. The consensus rating from analysts polled by S&P Global is a “Buy,” with not a single sell recommendation on the books. The average price target implies substantial upside from current levels. Piper Sandler has broken ranks, initiating coverage with a “Neutral” rating — a cautious stance that stands out against the broader optimism.
Should investors sell immediately? Or is it worth buying Rocket Lab?
That gap between analyst conviction and market price is unusually wide. Either the consensus is wrong, or the market has overreacted to short-term noise. The technical picture — an RSI below 31, a stock trading well below every major moving average — leans toward the latter interpretation.
Delays Are the Industry Norm
Investors punishing Rocket Lab for a potential Neutron delay may be ignoring the industry’s track record. Falcon 9, New Glenn, Vulcan, and Ariane 6 all missed their original first-flight targets by significant margins. Structural issues, propulsion setbacks, and supply-chain bottlenecks during qualification testing are standard fare for any new heavy-lift rocket program. Rocket Lab’s situation is less an outlier than a rite of passage.
The core business, meanwhile, is firing on all cylinders. Electron logged 36 new launch contracts between January and March alone, a record pace. That diversification provides a financial cushion while Neutron navigates its final development hurdles.
What Comes Next
The next major catalyst arrives on August 10, 2026, when Rocket Lab reports second-quarter results after the US market close. Investors will be looking for concrete updates on Neutron’s production status, as well as the integration progress from recent acquisitions. The earnings call could either validate the market’s worst fears or provide the clarity needed to reverse the slide.
For now, the stock sits at a level where the risk-reward calculus has shifted. A $2.2 billion backlog, a $266 million Air Force contract, a record-setting rapid-launch capability, and a rocket program that is following the industry’s standard development curve — none of that has stopped the selloff. But it does raise the question of how much bad news is already priced in.
Ad
Rocket Lab Stock: Buy or Sell?! New Rocket Lab Analysis from July 27 delivers the answer:
The latest Rocket Lab figures speak for themselves: Urgent action needed for Rocket Lab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 27.
Rocket Lab: Buy or sell? Read more here...
